Literature DB >> 16330703

Tuberculous pericarditis.

Bongani M Mayosi1, Lesley J Burgess, Anton F Doubell.   

Abstract

BACKGROUND: The incidence of tuberculous pericarditis is increasing in Africa as a result of the human immunodeficiency virus (HIV) epidemic. The primary objective of this article was to review and summarize the literature on the pathogenesis, diagnosis, and management of tuberculous pericarditis. METHODS AND
RESULTS: We searched MEDLINE (January 1966 to May 2005) and the Cochrane Library (Issue 1, 2005) for information on relevant references. A "definite" diagnosis of tuberculous pericarditis is based on the demonstration of tubercle bacilli in pericardial fluid or on a histological section of the pericardium; "probable" tuberculous pericarditis is based on the proof of tuberculosis elsewhere in a patient with otherwise unexplained pericarditis, a lymphocytic pericardial exudate with elevated adenosine deaminase levels, and/or appropriate response to a trial of antituberculosis chemotherapy. Treatment consists of the standard 4-drug antituberculosis regimen for 6 months. It is uncertain whether adjunctive corticosteroids are effective in reducing mortality or progression to constriction. Surgical resection of the pericardium remains the appropriate treatment for constrictive pericarditis. The timing of surgical intervention is controversial, but many experts recommend a trial of medical therapy for noncalcific pericardial constriction, and pericardiectomy in nonresponders after 4 to 8 weeks of antituberculosis chemotherapy.
CONCLUSIONS: Research is needed to improve the diagnosis, assess the effectiveness of adjunctive steroids, and determine the impact of HIV infection on the outcome of tuberculous pericarditis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330703     DOI: 10.1161/CIRCULATIONAHA.105.543066

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  100 in total

Review 1.  Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis.

Authors:  Massimo Imazio; Yehuda Adler
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

2.  Tailoring diagnosis and management of pericardial disease to the epidemiological setting.

Authors:  Faisal F Syed; Mpiko Ntsekhe; Bongani M Mayosi
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

3.  Porridge-like tuberculous cardiac tamponade: treatment difficulties in the Horn of Africa.

Authors:  Pierre-Laurent Massoure; Guillaume Boddaert; Jean-Luc Caumes; Pierre-Emmanuel Gaillard; Christophe Lions; Frédéric Grassin
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-06-13

4.  Images in cardiovascular medicine: Transkei heart.

Authors:  J P Smedema; V P Freeman
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

5.  Massive pericardial effusion as the only manifestation of primary hypothyroidism.

Authors:  Radheshyam Purkait; Anand Prasad; Ramchandra Bhadra; Arindam Basu
Journal:  J Cardiovasc Dis Res       Date:  2014-02-14

6.  Profile of cardiac disease in Cameroon and impact on health care services.

Authors:  Jacques Cabral Tantchou Tchoumi; Gianfranco Butera
Journal:  Cardiovasc Diagn Ther       Date:  2013-12

7.  Can tuberculosis still act as a hidden killer?

Authors:  Razia Aftab
Journal:  Int J Health Sci (Qassim)       Date:  2007-01

8.  Molecular detection of invasive aspergillosis in hematologic malignancies.

Authors:  P Badiee; P Kordbacheh; A Alborzi; M Ramzi; E Shakiba
Journal:  Infection       Date:  2008-10-14       Impact factor: 3.553

9.  Tuberculous pericarditis

Authors:  Leonardo F Jurado; Bibiana Pinzón; Zandra R De La Rosa; Marcela Mejía; Diana M Palacios
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935

10.  Viral genomes in the pericardial fluid and in peri- and epicardial biopsies from a German cohort of patients with large to moderate pericardial effusions.

Authors:  Sabine Pankuweit; Alexandra Stein; Konstantinos Karatolios; Anette Richter; Volker Ruppert; Bernhard Maisch
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.